Marksans Pharma Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Marksans Pharma Limited generated cash of $2,304,070,000, which is less than the previous year. Cash used in financing activities reached the amount of -$687,270,000 last year. Net change in cash is therefore $208,400,000.
Cash Flow
| 2010 | 169.19M | -353.25M | 315.63M |
|---|---|---|---|
| 2011 | -731.49M | 246.11M | 439.59M |
| 2012 | -622.96M | -32.54M | 570.15M |
| 2016 | 308.00M | -1.23B | -577.52M |
| 2018 | 589.20M | -387.79M | -54.26M |
| 2020 | 2.09B | -595.29M | -901.47M |
| 2021 | 1.78B | -448.95M | -152.85M |
| 2023 | 2.37B | -2.59B | 1.97B |
| 2024 | 2.30B | -1.40B | -687.27M |
MARKSANS.NS Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.82B | 2.06B | 937.27M | 328.54M | 251.62M | 1.85B | 309.21M | 355.00M | 223.43M |
Operating activities | |||||||||
Net income | 3.13B | 3.37B | 3.02B | 1.57B | 497.98M | 1.06B | -1.78B | -2.23B | -100.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 742.7M | 518.53M | 361.51M | 266.61M | 268.38M | 281.27M | 130.79K | 199.75M | 154.74M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -371.67M | -275.18M | -367.44M | -667.54M | 706.75M | -338.38M | 0 | 0 | 0 |
Inventories | -1.12B | -448.5M | -1.62B | 514.02M | -280.37M | -376.84M | -61.40M | 373.04M | 145.57M |
Accounts payable | 526.89M | 224.23M | 417.84M | 665.73M | -842.58M | 66.93M | 0 | 0 | 0 |
Cash generated by operating activities | 2.30B | 2.37B | 1.78B | 2.09B | 589.20M | 308.00M | -622.96M | -731.49M | 169.19M |
Investing activities | |||||||||
Purchases Of Investments | -370.01M | -1.89B | 0 | 0 | 0 | 0 | 0 | 100M | -100M |
Investments In Property Plant And Equipment | -2.08B | -536.31M | -464.24M | -596.26M | -389.35M | -1.31B | -52.79M | 129.38M | -268.69M |
Acquisitions Net | 0 | -266.1M | 5.2M | 2.82M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -1.40B | -2.59B | -448.95M | -595.29M | -387.79M | -1.23B | -32.54M | 246.11M | -353.25M |
Financing activities | |||||||||
Common Stock Issued | 0 | 2.74B | 0 | 703.04M | 0 | 0 | 11.56M | 44.91K | -2.15M |
Payments for dividends | -226.58M | -101.71M | -40.93M | -295.03M | -24.63M | -179.60M | -2.69M | 0 | 0 |
Repurchases of common stock | 0 | -451.66M | 0 | -50M | -10M | 0 | 0 | 0 | 0 |
Repayments of term debt | -124.97M | 52.96M | -1.02M | -810.66M | 170.68M | -334.97M | 0 | 0 | -243.64M |
Cash used in financing activities | -687.27M | 1.97B | -152.85M | -901.47M | -54.26M | -577.52M | 570.15M | 439.59M | 315.63M |
Net Change In Cash | 208.4M | 1.76B | 1.18B | 602.65M | 147.14M | -1.49B | -85.34M | -45.79M | 131.56M |
Cash at end of period | 4.03B | 3.82B | 2.12B | 931.20M | 398.76M | 353.01M | 223.86M | 309.21M | 355.00M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |